Rare diseases
Investigational molecules
Locations
Timolol maleate PH. EUR. is a chemically synthesised substance, classified as a beta-blocker under ATC code S01ED01.[1] In the trial registry it appears under the product names Timolol 0,5 % AT - 1 A Pharma, 5 mg/ml Augentropfen, Lösung and Timolol Micro Labs 5 mg/ml Augentropfen, Losung, authorised as a medicine in Germany.[1] The NHS dm+d browser lists a 0.25% eye drops formulation containing timolol maleate as the active ingredient.[2]
Timolol is a beta-blocker. Beta-blockers act on beta-adrenergic receptors in the body, and blocking these receptors can affect processes such as heart rate and blood pressure. In the context of this trial, timolol is used topically as part of dermatologic management, but the registry record does not describe its mechanism in skin side effects.[1]
In the trial, timolol is given as eye drops, solution for topical application or topical administration.[1] The NHS dm+d browser also records timolol 0.25% eye drops as a prescribable ocular product.[2]
One Phase 2 trial, 2023-505863-35-00, is authorised and plans to enrol 80 participants with locally advanced or metastatic Stage IIIB/C-IV EGFR-mutated NSCLC.[1] The study compares enhanced dermatologic management against standard-of-care skin management in people receiving first-line amivantamab plus lazertinib. Timolol is one of several topical and oral agents in the enhanced management arm. The primary outcome is the incidence of Grade ≥2 dermatologic adverse events of interest in the first 12 weeks after starting amivantamab and lazertinib.[1]
The supplementary source does not list side effects for timolol maleate, so no side-effect information is given here.[2]
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
